全文获取类型
收费全文 | 1525篇 |
免费 | 106篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 31篇 |
妇产科学 | 44篇 |
基础医学 | 169篇 |
口腔科学 | 30篇 |
临床医学 | 174篇 |
内科学 | 300篇 |
皮肤病学 | 21篇 |
神经病学 | 155篇 |
特种医学 | 70篇 |
外科学 | 319篇 |
综合类 | 22篇 |
一般理论 | 1篇 |
预防医学 | 78篇 |
眼科学 | 35篇 |
药学 | 70篇 |
中国医学 | 3篇 |
肿瘤学 | 77篇 |
出版年
2024年 | 2篇 |
2023年 | 11篇 |
2022年 | 17篇 |
2021年 | 43篇 |
2020年 | 43篇 |
2019年 | 62篇 |
2018年 | 69篇 |
2017年 | 36篇 |
2016年 | 57篇 |
2015年 | 53篇 |
2014年 | 101篇 |
2013年 | 98篇 |
2012年 | 160篇 |
2011年 | 172篇 |
2010年 | 77篇 |
2009年 | 58篇 |
2008年 | 92篇 |
2007年 | 105篇 |
2006年 | 86篇 |
2005年 | 85篇 |
2004年 | 69篇 |
2003年 | 61篇 |
2002年 | 46篇 |
2001年 | 7篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1987年 | 1篇 |
1984年 | 2篇 |
1982年 | 1篇 |
排序方式: 共有1639条查询结果,搜索用时 828 毫秒
11.
In this study, we reviewed autopsy records for clinical data and autopsy findings from patients aged 70 or more, over a 10-year period (1993 to 2002) in an urban university hospital. For that period, there were a total of 772 autopsy cases of which 180 (23%) patients were aged 70 years or older. We found that despite a marked decrease in total autopsy rates, there has been a perceptible rise in geriatric cases. Cardiovascular and infectious diseases in this age group are the leading causes of death as reported nationally. We found that women died more of acute myocardial infarctions than men, even though hypertensive and atherosclerotic cardiovascular diseases not otherwise specified were more prevalent in men. It is our conclusion that at our institution: 1) despite a marked decrease in the total autopsy rate, the geriatric autopsy rate is rising; 2) infectious and cardiovascular diseases are the leading causes of death in elderly patients; 3) Myocardial infarcts as a cause of death are more often seen in women for this age group. It is also our impression that better autopsy reporting is needed for maximal utilization of autopsy findings in medical auditing and teaching and for improvements in the quality of patient care in general and the geriatric patient in particular. 相似文献
12.
Gaurang Nandkishor Vaidya Lawrence S.C. Czer Daniel Luthringer Michelle Kittleson Jignesh Patel David H. Chang Evan Kransdorf Dael Geft Babak Azarbal Michele Hamilton Jon Kobashigawa 《Transplantation proceedings》2021,53(1):348-352
BackgroundGiant cell myocarditis (GCM) has a poor prognosis without heart transplant, but post-transplant survival is unknown.PurposeTo describe the post-transplant survival of patients with GCM at a large transplant center.MethodsSeven patients underwent heart transplant for histologically confirmed GCM of the explanted heart. The median age was 59 years, and 43% (3 of 7) were female. All patients had cardiogenic shock, multiorgan failure, elevated troponin, and recurrent ventricular tachycardia, and some required mechanical circulatory support. All patients received rabbit antithymocyte globulin (rATG) in the perioperative period at a dose of 1.5 mg/kg daily for 1 to 5 days and 4 received intravenous immunoglobulin 1 g/kg daily for 2 days after rATG. All patients had early initiation of tacrolimus by first to third postoperative day depending on renal function, early mycophenolate, and high dose steroid. All were maintained using tacrolimus, mycophenolate, and prednisone.ResultsOne patient had asymptomatic recurrence of GCM at 3 months, managed by up-titration of tacrolimus, and had asymptomatic 2R cellular rejection at 4 months, managed with steroid bolus. No patient had high-grade rejection. One patient died at 267 days, possibly of GCM. Six of 7 (86%) remain alive at a median of 842 days (2.3 years) post transplant.ConclusionsPatients with GCM have excellent post-transplant survival with use of rATG and triple drug immunosuppressive therapy; however, some patients remain at risk for GCM recurrence after transplant, which may respond to augmented immunosuppression. 相似文献
13.
Jignesh K. Patel Guillaume Coutance Alexandre Loupy Deanna Dilibero Michele Hamilton Michelle Kittleson Evan Kransdorf Babak Azarbal Osamu Seguchi Xiaohai Zhang David Chang Dael Geft Lawrence Czer Shaida Varnous Jon A. Kobashigawa 《American journal of transplantation》2021,21(7):2479-2488
Allosensitization represents a major barrier to heart transplantation (HTx). We assessed the efficacy and safety of complement inhibition at transplant in highly sensitized heart transplant recipients. We performed a single-center, single-arm, open-label trial (NCT02013037). Patients with panel reactive antibodies (PRA) ≥70% and pre–formed donor-specific antibodies (DSA) were eligible. In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant. The primary composite endpoint was antibody-mediated rejection (AMR) ≥pAMR2 and/or left ventricular dysfunction during the first year. Secondary endpoints included hemodynamic compromise, allograft rejection, and patient survival. Twenty patients were included. Median cPRA and mean fluorescence intensity of immunodominant DSA were 95% (90%–97%) and 6250 (5000–10 000), respectively. Retrospective B cell and T cell flow crossmatches were positive in 14 and 11 patients, respectively. The primary endpoint occurred in four patients (20%). Survival at 1 year was 90% with no deaths resulting from AMR. In a prespecified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR = 0.36, 95% CI = 0.14–0.95, p = .032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk. ClinincalTrials.gov, NCT02013037. 相似文献
14.
15.
16.
17.
18.
19.
20.